Abstract
Abstract PD-1 blockade with pembrolizumab achieves responses in 53% of patients with MMR-deficient tumors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
